TEL AVIV, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111’s potential utility as a targeted cancer treatment. The company presented two studies, one demonstrating the safety and specificity of VB-111 and the other demonstrating its promise against glioblastoma, at the American Association for Cancer Research (AACR) 102nd Annual Meeting, taking place this week in Orlando, Fla.
